Logo image of SKYE

SKYE BIOSCIENCE INC (SKYE) Stock Fundamental Analysis

USA - NASDAQ:SKYE - US83086J2006 - Common Stock

1.54 USD
+0.01 (+0.65%)
Last: 10/16/2025, 10:58:03 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SKYE. SKYE was compared to 536 industry peers in the Biotechnology industry. SKYE has a great financial health rating, but its profitability evaluates not so good. SKYE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SKYE has reported negative net income.
SKYE had a negative operating cash flow in the past year.
In the past 5 years SKYE always reported negative net income.
In the past 5 years SKYE always reported negative operating cash flow.
SKYE Yearly Net Income VS EBIT VS OCF VS FCFSKYE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

SKYE has a Return On Assets of -81.24%. This is in the lower half of the industry: SKYE underperforms 69.22% of its industry peers.
The Return On Equity of SKYE (-97.02%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -81.24%
ROE -97.02%
ROIC N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKYE Yearly ROA, ROE, ROICSKYE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SKYE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SKYE Yearly Profit, Operating, Gross MarginsSKYE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, SKYE has more shares outstanding
The number of shares outstanding for SKYE has been increased compared to 5 years ago.
SKYE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SKYE Yearly Shares OutstandingSKYE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SKYE Yearly Total Debt VS Total AssetsSKYE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -3.24, we must say that SKYE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.24, SKYE perfoms like the industry average, outperforming 44.96% of the companies in the same industry.
There is no outstanding debt for SKYE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.24
ROIC/WACCN/A
WACCN/A
SKYE Yearly LT Debt VS Equity VS FCFSKYE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

SKYE has a Current Ratio of 6.09. This indicates that SKYE is financially healthy and has no problem in meeting its short term obligations.
SKYE has a better Current ratio (6.09) than 63.62% of its industry peers.
SKYE has a Quick Ratio of 6.09. This indicates that SKYE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SKYE (6.09) is better than 64.18% of its industry peers.
Industry RankSector Rank
Current Ratio 6.09
Quick Ratio 6.09
SKYE Yearly Current Assets VS Current LiabilitesSKYE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

SKYE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.67%, which is quite impressive.
EPS 1Y (TTM)72.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1245%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -31.40% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-93.07%
EPS Next 2Y-36.41%
EPS Next 3Y-32.65%
EPS Next 5Y-31.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SKYE Yearly Revenue VS EstimatesSKYE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 100M 200M 300M
SKYE Yearly EPS VS EstimatesSKYE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SKYE. In the last year negative earnings were reported.
Also next year SKYE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKYE Price Earnings VS Forward Price EarningsSKYE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SKYE Per share dataSKYE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as SKYE's earnings are expected to decrease with -32.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-36.41%
EPS Next 3Y-32.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SKYE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SKYE BIOSCIENCE INC

NASDAQ:SKYE (10/16/2025, 10:58:03 AM)

1.54

+0.01 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners66.08%
Inst Owner Change0%
Ins Owners1.57%
Ins Owner Change0%
Market Cap47.72M
Analysts84.62
Price Target15.3 (893.51%)
Short Float %9%
Short Ratio8.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-371.23%
Min EPS beat(2)-746.82%
Max EPS beat(2)4.35%
EPS beat(4)3
Avg EPS beat(4)-166.09%
Min EPS beat(4)-746.82%
Max EPS beat(4)60.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.46%
EPS NY rev (1m)2.05%
EPS NY rev (3m)-12.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-3.31
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.24%
ROE -97.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 259.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.09
Quick Ratio 6.09
Altman-Z -3.24
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)207.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1245%
EPS Next Y-93.07%
EPS Next 2Y-36.41%
EPS Next 3Y-32.65%
EPS Next 5Y-31.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-169.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.27%
OCF growth 3YN/A
OCF growth 5YN/A